Effect of reovirus on lymphoid tumors in SCID/NOD mice.

(A-B) Intratumoral reovirus therapy of lymphoid tumors in SCID/NOD mice. SCID/NOD mice were subcutaneously implanted with 1 × 10⁷ cells of either Raji (A) or Daudi (B) Burkitt lymphoma cell lines. Following the establishment of a palpable mass, the tumors received (on day 0) a single intratumoral injection of 1 × 10⁷ PFUs of live reovirus (n = 8; ●) or UV-inactivated virus (n = 7; ○). Tumor growth was followed for a period of 30 days and measured 2-dimensionally with a caliper. (C) Intravenous administration of reovirus to SCID/NOD mice bearing Raji tumors. Animals bearing palpable subcutaneous Raji tumors were subjected (on day 0) to a single intravenous injection of 1 × 10⁷ PFUs (n = 7) or 5 × 10⁷ PFUs (n = 7) of reovirus (● and ▴, respectively). Control animals (n = 7) received saline injection (○). Tumor growth was followed for a period of 20 days and measured 2-dimensionally with a caliper. (D) H&E staining and IH of reovirus antigens in Raji tumors after intravenous reovirus treatment. H&E-stained section (original magnification × 400) shows necrosis of tumor cells 20 days after live reovirus treatment. IH-stained section (original magnification × 400) of remaining tumor cells stains positively for reovirus proteins (brown) while control tumor shows no staining.